



Expert Forum 2019

Cell therapy: Innovating the treatment of DLBCL and PMBCL with CAR T

Agenda

This meeting is a promotional meeting that includes discussion of YESCARTA®, organised and fully funded by Gilead Sciences Europe Ltd

© 2018 Kite Pharma, Inc.



Agenda Day 1 (Friday, 8 March)

Time	Topic	Speaker
12:00–12:45	LUNCH (then transition to plenary room)	
13:00–13:10	Chair's welcome	Andrew Davies UK)
	SESSION 1: TREATMENT LANDSCAPE AND OPPORTUNITIES FOR CAR T	
13:10–13:30	DLBCL/PMBCL unmet needs and current treatment options	Michele Ghielmini (Switzerland)
13:30–13:45	CAR T cell overview: Structure and mechanism of action	Álvaro Urbano (Spain)
	SESSION 2: OPTIMISING OUTCOMES WITH CAR T THERAPY	
13:45–14:05	Understanding data from pivotal trials	Marie Jose Kersten (Netherlands) TBC or Max Topp (Germany)
14:05–14:35	Managing CAR T therapy-related adverse events	Michael Bishop (USA)
14:35–14:50	Health economics and CAR T therapy 1) <i>Understanding cost effectiveness analyses</i>	Anthony Hatswell (UK)
14:50–15:05	2) <i>Emerging data on the value of cell therapy in B-cell malignancies</i>	Pier Luigi Zinzani (Italy)
15:05–15:20	Panel discussion Q&A	All
15:20–15:50	COFFEE BREAK	
	SESSION 3: IDENTIFYING THE CAR T PATIENT (CASE STUDIES)	
15:50–16:05	Considerations in identifying patients for CAR T therapy	Marion Subklewe (Germany)
16:05–16:35	Illustrative CAR T patient case studies (x2)	Max Topp (Germany) Steven Le Gouill (France)
16:35–16:55	Panel discussion Q&A	All
	SESSION 4: PATIENT AND PHYSICIAN CLINICAL PERSPECTIVES	
16:55–17:15	Our journey with CAR T therapy	Dimas & Michael Bishop (USA)
17:15–17:30	Closing remarks for Day 1	Andrew Davies (UK)

Agenda Day 2 (Saturday, 9 March)

Time	Topic	Speaker
08:30–08:40	Chair's welcome to Day 2	Marion Subklewe (Germany)
	SESSION 5: UNDERSTANDING THE CAR T CELL JOURNEY	
08:40–09:05	The CAR T cell journey	Catherine Thieblemont (France) & Marc Kamp (Kite)
09:05–09:15	Panel discussion Q&A	All
	SESSION 6: WORKSHOP 1	
09:15–09:20	Introduction to workshops (then transition to workshop rooms)	Marion Subklewe (Germany)
09:30–10:30	Workshop rotation 1: Real-world management of AEs	TBC
10:30–11:00	COFFEE BREAK	
	SESSION 7: MANAGING CAR T THERAPY: THE EUROPEAN EXPERIENCE IN DLBCL	
11:00–11:20	Referral and delivery centre collaboration	Andrew Davies (UK)
11:20–11:45	Optimising team management of the CAR T patient	Marcus Taylor (Kite) and Reuben Benjamin (UK)
11:45–12:00	Panel discussion Q&A	All
12:00–13:00	LUNCH (then transition to workshop rooms)	
	SESSION 8: WORKSHOP 2	
13:10–14:10	Workshop rotation 2: Patient selection, referral and preparation (then transition to plenary room)	TBC
	SESSION 9: FUTURE PERSPECTIVES FOR CELL THERAPY	
14:20–14:45	The future of cancer care: New technologies in cell therapy	TBC
14:45–14:55	Panel discussion Q&A	All
14:55–15:00	Summary and closing thoughts	Marion Subklewe (Germany)